+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID04911816

Phase 12 Study of Pre-Surgery mFOLFIRINOX with Oral Hydroxychloroquine in Treating Resectable Pancreatic Adenocarcinoma

Led by West Virginia University · Updated on 2026-04-20

40

Participants Needed

1

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety and tolerability of a combination treatment using pre-operative mFOLFIRINOX chemotherapy with peri-operative oral hydroxychloroquine FHQ for people diagnosed with resectable adenocarcinoma of the pancreas. This phase III trial aims to understand how these treatments work together before surgery and to evaluate the tumor response through detailed tissue analysis after surgery. Participants are carefully selected based on imaging and biopsy results to confirm the cancer is resectable and without major vessel involvement. Participants will receive daily oral hydroxychloroquine alongside four cycles of mFOLFIRINOX chemotherapy over 56 days before surgery. Hydroxychloroquine dosing will be escalated using a 33 algorithm to find the maximum tolerated dose, with doses ranging from 400 mg to 1200 mg per day. After chemotherapy, patients will undergo surgical exploration and tumor removal if feasible. Hydroxychloroquine will continue for two weeks after surgery. Following surgery, subjects will have repeat scans 10 to 14 weeks later and then receive standard adjuvant therapy as decided by their doctors. During the study, participants will be monitored closely with imaging scans, blood tests, and pathology assessments of the removed tumor tissue to evaluate treatment effects and safety. The study tracks key outcomes such as the maximum tolerated dose of hydroxychloroquine, histopathological tumor response, and biochemical tumor markers. The total study period includes the neoadjuvant treatment phase, surgery, postoperative monitoring, and follow-up imaging to assess long-term effects. Participants health will be followed carefully throughout the trial duration, which may last until 2030.

CONDITIONS

Brief Title

Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma

Research Team

B

Brian Boone

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here